Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion type Assertion NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_head.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion description "[The distribution of the treatment-related MDS cases was different than de novo MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_provenance.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion evidence source_evidence_literature NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_provenance.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion SIO_000772 3504435 NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_provenance.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion wasDerivedFrom befree-2016 NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_provenance.
- NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_assertion wasGeneratedBy ECO_0000203 NP1302695.RAGoK8GL3BenSEiIBq-ATugXZU2NLdaHIgFXM-gr1A-XU130_provenance.